Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14432835 | 1.00 | MDM4 (0.59) | MDM4TP53SLC17A5CASP3KMT2A | |
| SCHEMBL18881272 | 0.94 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3KMT2A | |
| SCHEMBL3436129 | 0.91 | MDM4 (0.58) | MDM4TP53SLC17A5CASP3KMT2A | |
| SCHEMBL29400770 | 0.91 | MDM4 (0.58) | MDM4TP53SLC17A5CASP3KMT2A | |
| SCHEMBL1001473 | 0.91 | MDM4 (0.58) | MDM4TP53SLC17A5CASP3KMT2A | |
| SCHEMBL30665728 | 0.90 | MDM4 (0.51) | MDM4TP53SLC17A5CASP3KMT2A | |
| SCHEMBL16310689 | 0.90 | MDM4 (0.57) | MDM4TP53SLC17A5CASP3KMT2A | |
| SCHEMBL10020438 | 0.90 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL1739174 | 0.90 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL22154133 | 0.89 | MDM4 (0.56) | MDM4TP53SLC17A5CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230219-A1 | TOLL-LIKE RECEPTOR 2 LIGANDS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2021-07-29 | — | — | US | disclosed |
| US-10793595-B2 | Toll-like receptor 2 ligands and methods of making and using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190263857-A1 | TOLL-LIKE RECEPTOR 2 LIGANDS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2019-08-29 | — | — | US | disclosed |
| US-20180051055-A1 | TOLL-LIKE RECEPTOR 2 LIGANDS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-02-22 | — | — | US | disclosed |
| US-9127039-B2 | Sulfur-containing amino acid derivative | AJINOMOTO CO., INC. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20130071863-A1 | Sulfur-Containing Amino Acid Derivative | AJINOMOTO CO., INC. (JP) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071863-A1 | Sulfur-Containing Amino Acid Derivative | SLC7A5, CTH, CBS | MDM4 1996/4885TP53 3873/4885SLC17A5 358/4885 |
| US-20180051055-A1 | TOLL-LIKE RECEPTOR 2 LIGANDS AND METHODS OF MAKING AND USING THEREOF | TLR2, TLR3, TLR4 | MDM4 3491/4885TP53 275/4885SLC17A5 1941/4885 |
| US-20190263857-A1 | TOLL-LIKE RECEPTOR 2 LIGANDS AND METHODS OF MAKING AND USING THEREOF | TLR2, TLR3, TLR4 | MDM4 3491/4885TP53 275/4885SLC17A5 1941/4885 |
| US-20210230219-A1 | TOLL-LIKE RECEPTOR 2 LIGANDS AND METHODS OF MAKING AND USING THEREOF | TLR2, TLR3, TLR4 | MDM4 3491/4885TP53 275/4885SLC17A5 1941/4885 |
| US-10793595-B2 | Toll-like receptor 2 ligands and methods of making and using thereof | TLR2, TLR3, TLR4 | MDM4 3491/4885TP53 275/4885SLC17A5 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.